EuroBiotech—More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> Lundbeck offloaded two preclinical programs to AstraZeneca. The deal continues Lundbeck’s push to shed assets that are outside of its area of focus. Statement

> UniQure presented data on its hemophilia B gene therapy program. The data suggest the vector used by uniQure achieves liver transduction in the presence of pre-existing anti-AAV5 neutralizing antibodies. Release 

> 4D Pharma gained clearance to trial a commensal bacteria strain in cancer patients. The trial will look at the immunomodulatory effects of MRx0518 in people with solid tumors. Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Sensorion raised €8.7 million ($10.2 million). The money will fund the completion of a phase 2 trial of SENS-111 in patients with rare ear disease vestibular neuritis. Release 

> Cellectis gained clearance to increase the dose levels in a phase 1 trial of off-the-shelf CAR-T drug UCART123. The French biotech is also opening another site in a bid to increase the speed of enrollment. Statement 

Suggested Articles

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial.